Opus Genetics, Inc.

IRD ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2018 FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Revenue $0 $0 $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $13.1M $10.7M $10.1M $12.1M $7.0M $3.3M $3.4M $12.0M
SG&A Expense $7.4M $6.6M $6.3M $6.1M $6.3M $4.7M $2.7M $3.5M
Operating Income $-20.5M $-17.4M $-16.4M $-18.3M $-13.3M $-8.0M $-6.6M $-16.1M
Operating Margin
Interest Expense
Pretax Income
Income Tax Expense $0 $0 $0
Net Income $-14.4M $-25.3M $-9.3M $-14.4M $-18.5M $-9.5M $-6.2M $-11.3M
Net Margin
EPS (Basic) $-0.88 $-0.15 $-0.07 $-0.13 $-0.02 $-0.01 $-0.01 $-0.02
EPS (Diluted) $-0.88 $-0.15 $-0.07 $-0.13 $-0.02 $-0.01 $-0.01 $-0.02
Shares Outstanding (Basic) 18.7M 190.4M 142.4M 1.18B 1.07B 880.3M 716.6M 572.1M
Shares Outstanding (Diluted) 18.7M 190.4M 142.4M 1.18B 1.07B 880.3M 716.6M 572.1M
Dividends Per Share
← Newer Page 2 of 4 Older →